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Background
Induction of immune tolerance as therapeutic approach
for autoimmune diseases constitutes a current research
focal point. JIA is the most common chronic rheumatic
disorder in children and is also a major cause of
acquired disability and impairment of quality of life in
childhood.
Aim
In this sense, we aimed to evaluate an Altered Peptide
Ligand (APL) for induction of peripheral tolerance in
patients with Juvenile idiopathic Arthritis (JIA).
Methods
First, a novel T cell epitope from human heat-shock
protein 60 (Hsp60), an autoantigen involved in the
pathogenesis of JIA and other autoimmune diseases, was
identified by bioinformatics tools and an APL was
design starting from this epitope. We evaluated the ther-
apeutic effect of this peptide in an adjuvant-induced
arthritis (AA) rat model. Clinical score, TNFa levels and
histopathology were monitored. Also the potentialities
of the APL for inducing regulatory T cells were evalu-
ated in ex vivo assays using peripheral blood mononuc-
lear cells (PBMC) from JIA patients.
Results
The APL efficiently inhibited the course of AA in rat,
with significant reduction of the clinical and histopath-
ogy score. This effect was associated with a decrease of
TNFa levels in spleen. Finally, stimulation of PBMCs
from JIA patients by the APL increases the proportions
of the CD4+CD25
high FoxP3+ Treg cells.
Conclusion
These results indicate a therapeutic potentiality of APL
and support further investigation of this candidate drug
for treatment of JIA and other autoimmune diseases.
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